shutterstock_619078730_melinda_nagy

Melinda Nagy / Shutterstock.com

8 April 2021Big PharmaMuireann Bolger

UK govt’s £20m fund for life sciences opens for applications

The UK government’s £20 million fund aimed at growing life sciences manufacturing is now open for applications, it confirmed today, April 7.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More on this story

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More on this story

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages